

United Imaging (688271 CH)

Robust overseas growth offset soft domestic demand

United Imaging (UIH) reported 1H26 revenue of RMB7,052mn, up 17% YoY, representing 42% of our prior full-year forecast and below the ~47% historical average. Overseas revenue remained strong, up 54.5% YoY while domestic revenue grew a modest 8.5% YoY against a weak domestic market. Attributable net profit decreased 10% YoY to RMB897mn, primarily due to FX losses. On an ex-FX basis, bottom-line grew a resilient 9% YoY. Given weaker-than-expected domestic procurement in 1H26 and the lag between tender wins and revenue recognition, we lower our 2026E revenue forecast by 3.7%. We also cut our 2026E earnings forecast by 6.8%, reflecting the FX losses already recorded in 1H26 and near-term gross margin pressure from broader domestic centralized procurement, although we expect FX headwinds to moderate in 2H26E. Looking ahead, we believe that the sales mix shifts to mid- to high-end products and services should help offset centralized procurement-related margin pressure in the long term.

- **Overseas growth remained strong, with improving margins.** Overseas revenue increased 54.5% YoY to RMB1,765mn, expanding the overseas revenue mix by 6ppts to 25% (+6ppts YoY). The robust growth was primarily driven by APAC (+148.5% YoY) and Europe (+49.4% YoY). Service revenue overseas increased 64% YoY, driven by a growing installed base. Notably, favorable mix toward mid- to high-end products, together with improving localization and operating efficiency, drove overseas gross margin up by over 3ppts YoY. The order intake remained healthy, with mix continuing to shift toward higher-end products. We therefore expect overseas revenue growth to remain strong in 2H26.
- **Domestic share gains led by high-end products.** Domestic revenue grew 8.5% YoY to RMB5,287mn despite a weak market in 1H26, with UIH gaining 1.7ppts of domestic market share YoY. Share gains were particularly notable in high-end products such as 3.0T MR (+1.5ppts), PET/MR (+40 ppts), DSA (+6ppts). In addition, we believe UIH's increasing revenue mix of mid- and high-end products should help mitigate the margin pressure from centralized procurement over time. According to MDDi, the domestic market for medical imaging equipment declined 15.8% YoY in 1H26. Given the high base in 2H25 and the tender-to-revenue lag, we expect 2H26E domestic revenue will inevitably face growth pressure. However, the recovery in procurement activities since July should support solid growth in late-2H26E and 1H27E.
- **Maintain BUY.** We lower our 2026E earnings forecasts to reflect near-term FX losses and pressure from centralized procurement, but remain positive on UIH's long-term growth. We therefore lower TP to RMB154.95 based on a 9-year DCF model (WACC: 8.1%, terminal growth: 4.0%).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	10,300	13,800	16,283	19,484	23,232
YoY growth (%)	(9.7)	34.0	18.0	19.7	19.2
Attributable net profit (RMB mn)	1,262	1,869	2,121	2,538	3,152
YoY growth (%)	(36.1)	48.1	13.5	19.7	24.2
EPS (Reported) (RMB)	1.54	2.28	2.57	3.08	3.82
P/E (x)	71.4	48.2	42.7	35.7	28.8
Net gearing (%)	(39.4)	(21.1)	(23.6)	(23.6)	(24.3)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB154.95
(Previous TP) RMB161.04)
Up/Downside 40.9%
Current Price RMB109.99

China Healthcare

Jill WU, CFA
(852) 3900 0842
jillwu@cmbi.com.hk

Cathy WANG
(852) 3916 1729
cathywang@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	90,649.1
Avg 3 mths t/o (RMB mn)	917.9
52w High/Low (RMB)	158.30/98.23
Total Issued Shares (mn)	824.2

Source: FactSet

Shareholding Structure

United Imaging Group	20.3%
Shanghai Alliance Investment Ltd	16.4%


Source: SSE

Share Performance

	Absolute	Relative
1-mth	-6.8%	-9.4%
3-mth	-1.8%	4.7%
6-mth	-12.7%	-8.7%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	16,283	19,484	23,232	16,902	20,359	24,370	-3.66%	-4.30%	-4.67%
Gross profit	7,687	9,247	11,082	7,980	9,679	11,684	-3.67%	-4.46%	-5.15%
Operating profit	2,248	2,690	3,341	2,411	2,980	3,685	-6.76%	-9.71%	-9.33%
Net profit	2,121	2,538	3,152	2,275	2,811	3,477	-6.76%	-9.71%	-9.33%
EPS (RMB)	2.57	3.08	3.82	2.76	3.41	4.22	-6.76%	-9.71%	-9.33%
Gross margin	47.21%	47.46%	47.70%	47.21%	47.54%	47.94%	-0.01ppt	-0.08ppt	-0.24ppt
Operating margin	13.81%	13.81%	14.38%	14.26%	14.64%	15.12%	-0.46ppt	-0.83ppt	-0.74ppt
Net margin	13.03%	13.03%	13.57%	13.46%	13.81%	14.27%	-0.43ppt	-0.78ppt	-0.7ppt

Source: CMBIGM estimates

Figure 2: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
EBIT	2,327	2,629	3,272	4,036	4,921	5,970	7,221	8,706	10,462
Tax rate	6.93%	6.93%	6.93%	6.93%	6.93%	6.93%	6.93%	6.93%	6.93%
EBIT*(1-tax rate)	2,166	2,447	3,045	3,756	4,580	5,556	6,720	8,103	9,737
+ D&A	555	662	758	846	925	996	1,061	1,120	1,173
- Change in working capital	-16	-869	-1,162	-1,186	-1,225	-1,246	-1,250	-1,216	-1,128
- Capex	-1,500	-1,500	-1,500	-1,500	-1,500	-1,500	-1,500	-1,500	-1,500
FCFF	1,205	739	1,141	1,916	2,780	3,807	5,031	6,507	8,282
Terminal value									208,732

Terminal growth rate	4.0%
WACC	8.1%
Cost of Equity	10.9%
Cost of Debt	3.5%
Equity Beta	0.80
Risk Free Rate	2.5%
Market Risk Premium	10.5%
Target Debt to Asset ratio	35.0%
Effective Corporate Tax Rate	15.0%

Terminal value	103,326
Total PV	122,133
Net debt	-5,528
Minority	-39
Equity value	127,699
# of shares (mn)	824
DCF per share (in RMB)	154.95

Source: CMBIGM estimates

Figure 3: Sensitivity analysis

		WACC				
		7.1%	7.6%	8.1%	8.6%	9.1%
Terminal growth rate	5.0%	298.03	237.60	196.64	167.09	144.79
	4.5%	246.16	203.61	172.92	149.77	131.71
	4.0%	210.87	178.99	154.95	136.19	121.17
	3.5%	185.32	160.34	140.86	125.26	112.51
	3.0%	165.96	145.72	129.52	116.27	105.26

Source: CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	16,283	19,484	23,232	16,670	20,092	24,263	-2.32%	-3.03%	-4.25%
Gross profit	7,687	9,247	11,082	7,960	9,708	11,872	-3.43%	-4.74%	-6.66%
Operating profit	2,248	2,690	3,341	2,456	3,077	3,865	-8.46%	-12.57%	-13.56%
Net profit	2,121	2,538	3,152	2,304	2,898	3,667	-7.95%	-12.42%	-14.04%
EPS (RMB)	2.57	3.08	3.82	2.86	3.57	4.50	-10.08%	-13.73%	-14.95%
Gross margin	47.21%	47.46%	47.70%	47.75%	48.32%	48.93%	-0.54ppt	-0.86ppt	-1.23ppt
Operating margin	13.81%	13.81%	14.38%	14.73%	15.31%	15.93%	-0.93ppt	-1.51ppt	-1.55ppt
Net margin	13.03%	13.03%	13.57%	13.82%	14.42%	15.11%	-0.8ppt	-1.4ppt	-1.55ppt

Source: Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	11,411	10,300	13,800	16,283	19,484	23,232
Cost of goods sold	(6,039)	(5,300)	(7,313)	(8,597)	(10,237)	(12,151)
Gross profit	5,372	5,000	6,488	7,687	9,247	11,082
Operating expenses	(3,230)	(3,634)	(4,487)	(5,439)	(6,557)	(7,740)
Selling expense	(1,609)	(1,823)	(2,261)	(2,605)	(3,078)	(3,624)
Admin expense	(561)	(556)	(627)	(733)	(867)	(1,022)
R&D expense	(1,729)	(1,761)	(1,842)	(2,166)	(2,572)	(3,043)
Others	668	507	243	65	(39)	(51)
Operating profit	2,142	1,366	2,000	2,248	2,690	3,341
Others	1	(15)	(19)	0	0	0
Pre-tax profit	2,142	1,352	1,981	2,248	2,690	3,341
Income tax	(164)	(110)	(137)	(156)	(186)	(232)
Minority interest	(3)	20	25	29	34	43
Attributable net profit	1,974	1,262	1,869	2,121	2,538	3,152
Adjusted net profit	1,665	1,010	1,770	2,088	2,442	3,056

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Current assets	20,228	20,894	22,873	23,874	25,766	28,368
Cash & equivalents	7,584	8,400	5,503	6,127	6,632	7,455
Account receivables	3,233	4,360	5,682	5,478	6,021	6,861
Inventories	3,893	5,528	5,729	6,359	7,292	8,322
Prepayment	148	196	264	264	264	264
Other current assets	5,370	2,410	5,695	5,645	5,556	5,466
Non-current assets	5,108	7,142	9,912	10,750	11,588	12,330
PP&E	2,212	2,944	3,228	4,349	5,364	6,281
Deferred income tax	399	439	475	475	475	475
Intangibles	828	1,004	1,513	1,363	1,213	1,063
Goodwill	22	22	22	22	22	22
Other non-current assets	1,647	2,732	4,674	4,541	4,515	4,489
Total assets	25,336	28,036	32,785	34,624	37,354	40,698
Current liabilities	5,798	7,076	9,280	9,345	9,952	10,660
Short-term borrowings	9	557	945	600	600	600
Account payables	1,919	2,608	2,769	3,180	3,786	4,494
Tax payable	399	327	640	640	640	640
Other current liabilities	3,471	3,584	4,926	4,926	4,926	4,926
Non-current liabilities	657	1,054	1,943	1,943	1,943	1,943
Long-term borrowings	0	0	0	0	0	0
Deferred income	514	461	475	475	475	475
Other non-current liabilities	143	592	1,468	1,468	1,468	1,468
Total liabilities	6,455	8,129	11,223	11,288	11,895	12,603
Share capital	824	824	824	824	824	824
Capital surplus	412	412	412	412	412	412
Reserves	13,910	13,947	13,957	15,760	17,917	20,596
Others	3,720	4,719	6,379	6,379	6,379	6,379
Total shareholders equity	18,866	19,903	21,572	23,375	25,532	28,211
Minority interest	15	3	(10)	(39)	(73)	(116)
Total equity and liabilities	25,336	28,036	32,785	34,624	37,354	40,698

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	1,978	1,242	1,844	2,092	2,504	3,109
Depreciation & amortization	262	424	570	555	662	758
Tax paid	(164)	(110)	(137)	(156)	(186)	(232)
Change in working capital	(2,258)	(2,342)	118	(16)	(869)	(1,162)
Others	315	166	284	302	125	162
Net cash from operations	133	(619)	2,679	2,777	2,235	2,636
Investing						
Capital expenditure	(1,076)	(1,946)	(2,093)	(1,500)	(1,500)	(1,500)
Acquisition of subsidiaries/ investments	(45)	(10)	0	0	0	0
Net proceeds from disposal of short-term investments	25,308	26,853	34,799	20,000	20,000	20,000
Others	(25,752)	(26,141)	(36,063)	(19,910)	(19,910)	(19,910)
Net cash from investing	(1,565)	(1,244)	(3,357)	(1,410)	(1,410)	(1,410)
Financing						
Dividend paid	(166)	(304)	(176)	(397)	(319)	(403)
Net borrowings	4	546	385	(345)	0	0
Proceeds from share issues	10	94	12	0	0	0
Others	(511)	(136)	(68)	0	0	0
Net cash from financing	(662)	199	153	(742)	(319)	(403)
Net change in cash						
Cash at the beginning of the year	9,626	7,531	5,868	5,503	6,127	6,632
Exchange difference	(1)	2	(32)	0	0	0
Cash at the end of the year	7,531	5,868	5,310	6,127	6,632	7,455
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	23.5%	(9.7%)	34.0%	18.0%	19.7%	19.2%
Gross profit	20.2%	(6.9%)	29.8%	18.5%	20.3%	19.8%
Operating profit	11.1%	(36.2%)	46.4%	12.4%	19.7%	24.2%
Net profit	19.2%	(36.1%)	48.1%	13.5%	19.7%	24.2%
Adj. net profit	25.4%	(39.3%)	75.2%	18.0%	16.9%	25.1%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	47.1%	48.5%	47.0%	47.2%	47.5%	47.7%
Operating margin	18.8%	13.3%	14.5%	13.8%	13.8%	14.4%
Adj. net profit margin	14.6%	9.8%	12.8%	12.8%	12.5%	13.2%
Return on equity (ROE)	10.9%	6.5%	9.0%	9.4%	10.4%	11.7%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.4)	(0.4)	(0.2)	(0.2)	(0.2)	(0.2)
Current ratio (x)	3.5	3.0	2.5	2.6	2.6	2.7
Receivable turnover days	84.2	134.5	132.8	122.8	112.8	107.8
Inventory turnover days	222.2	324.4	280.9	270.0	260.0	250.0
Payable turnover days	124.3	155.9	134.2	135.0	135.0	135.0
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	45.8	71.4	48.2	42.7	35.7	28.8
P/E (diluted)	45.8	71.4	48.2	42.7	35.7	28.8
P/B	4.8	4.5	4.2	3.9	3.6	3.2
P/CFPS	682.8	ns	33.7	32.6	40.6	34.4
Div yield (%)	0.8	0.2	0.3	0.4	0.4	0.5

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.